Evolution of [<sup>18</sup>F]fluorodeoxyglucose and [<sup>18</sup>F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy
Creators: name: Perri, Dario Di
name: Lee, John A.
name: Bol, Anne
name: François-Xavier Hanin
name: Janssens, Guillaume
name: Labar, Daniel
name: Robert, Annie
name: Sterpin, Edmond
name: Geets, Xavier
Publisher: name: Taylor & Francis
Year: 2017
Subjects: subject: Space Science
subject: Medicine
subject: Cell Biology
subject: Pharmacology
subject: 59999 Environmental Sciences not elsewhere classified
subject: FOS: Earth and related environmental sciences
subject: FOS: Earth and related environmental sciences
subject: Sociology
subject: FOS: Sociology
subject: FOS: Sociology
subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Cancer
subject: 111714 Mental Health
subject: FOS: Health sciences
subject: FOS: Health sciences

description: <b>Background:</b> Dose painting (DP) aims to improve radiation therapy (RT) outcome by targeting radioresistant tumour regions identified through functional imaging, e.g., positron emission tomography (PET). Importantly, the expected benefit of DP relies on the ability of PET imaging to identify tumour areas which could be consistently targeted throughout the treatment. In this study, we analysed the spatial stability of two potential DP targets in lung cancer patients undergoing RT: the tumour burden surrogate [<sup>18</sup>F]fluorodeoxyglucose (FDG) and the hypoxia surrogate [<sup>18</sup>F]fluoroazomycin arabinoside (FAZA). <b>Materials and methods:</b> Thirteen patients with unresectable lung tumours underwent FDG and FAZA 4D-PET/CT before (pre), and during the second (w2) and third (w3) weeks of RT. All PET/CT were reconstructed in their time-averaged midposition (MidP) for further analysis. The metabolic tumour volume (MTV: FDG standardised uptake value (SUV) &gt; 50% SUV<sub>max</sub>) and the hypoxic volume (HV: FAZA SUV &gt;1.4) were delineated within the gross tumour volume (GTV<sub>CT</sub>). The stability of FDG and FAZA PET uptake distributions during RT was subsequently assessed through volume-overlap analysis and voxel-based correlation analysis. <b>Results:</b> The volume-overlap analysis yielded median overlapping fraction (OF) of 0.86 between MTV<sub>pre</sub> and MTV<sub>w2</sub> and 0.82 between MTV<sub>pre</sub> and MTV<sub>w3</sub>. In patients with a detectable HV, median OF was 0.82 between HV<sub>pre</sub> and HV<sub>w2</sub> and 0.90 between HV<sub>pre</sub> and HV<sub>w3</sub>. The voxel-based correlation analysis yielded median Spearman’s correlation coefficient (r<sub>S</sub>) of 0.87 between FDG<sub>pre</sub> and FDG<sub>w2</sub> and 0.83 between FDG<sub>pre</sub> and FDG<sub>w3</sub>. Median r<sub>S</sub> was 0.78 between FAZA<sub>pre</sub> and FAZA<sub>w2</sub> and 0.79 between FAZA<sub>pre</sub> and FAZA<sub>w3</sub>. <b>Conclusions:</b> FDG and FAZA PET uptake distributions were spatially stable during the 3 first weeks of RT in patients with unresectable lung cancer, both based on volume- and voxel-based indicators. This might allow for a consistent targeting of high FDG or FAZA PET uptake regions as part of a DP strategy.